MoonLake Immunotherapeutics
MLTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$11.85
KIRA · Stoqly’s AI analyst, in plain words
- MoonLake Immunotherapeutics lost $227M in fiscal 2025.
- Free cash flow was −$196M in fiscal 2025, — of revenue.
- MoonLake Immunotherapeutics has $320M more cash than debt.
Market cap
$876M
P/E
—
Revenue
—
Net income
−$227M
Free cash flow
−$196M
Operating margin
—
MoonLake Immunotherapeutics in 30 seconds · fiscal 2025
Does it make a profit?
−$227M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MoonLake Immunotherapeutics does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- MoonLake Immunotherapeutics
- CIK
- 0001821586
MoonLake Immunotherapeutics · MLTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$4.5M | −$50.0M | −$36.0M | −$119M | −$227M |
| Diluted EPS | −$0.31 | −$1.70 | −$0.73 | −$1.89 | −$3.53 |
| Cash | |||||
| Cash from operations | −$0.6M | −$55.9M | −$42.8M | −$117M | −$196M |
| Capital expenditure | — | $0.0M | $0.3M | $0.5M | $0.0M |
| Free cash flow | — | −$55.9M | −$43.1M | −$117M | −$196M |
| Share buybacks | — | $0.0M | $0.0M | $0.0M | — |
| Share count change | — | −91.8% | 67.3% | 28.0% | 2.5% |
| Debt and strength | |||||
| Cash and short-term investments | $8.0M | $72.1M | $511M | $448M | $394M |
| Debt incl. finance leases | $15.0M | $0.0M | — | $0.0M | $74.1M |
| Shareholders' equity | −$11.6M | $48.9M | $496M | $447M | $304M |
| Current ratio | 0.5x | 10.0x | 51.6x | 21.1x | 9.3x |
| Interest coverage | — | — | — | — | −33.8x |
| Returns and quality | |||||
| Return on equity | — | −268.3% | −13.2% | −25.2% | −60.5% |
| Return on tangible equity | — | −102.2% | −7.3% | −26.6% | −74.7% |
| Piotroski F-score | — | 3 | — | — | 1 |
| Altman Z'' | −29.6 | 3.1 | 44.8 | 21.7 | 1.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$83.0M
4 insiders
Of sales under plans
14%
$11.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MoonLake Immunotherapeutics · MLTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.85 a share, the company is worth $876M.
Source: SEC EDGAR XBRL filings (CIK 0001821586). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.